Interview with Melvin Oscar D'souza, Managing Director, Novo Nordisk India…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Address: Novo Nordisk India Limited, Plot No.32, 47-50, EPIP Area, Whiltefield, Bangalore – 560 066, India
Tel: +91 80 4030 3200
Web: http://www.novonordisk.co.in/documents/home_page/document/index.asp
Novo Nordisk India story
The genesis of Novo Nordisk India goes back to 1990 when a liaison office of Novo Nordisk A/S, was set up in Mumbai. Prior to this Novo Nordisk A/S products were marketed in India through various other companies. Even then, Novo Nordisk was involved in creating awareness in diabetes care with the help of healthcare professionals in India.
On April 1, 1994, Novo Nordisk (I) Pvt. Ltd. was set up with its headquarters in Bangalore with 26 employees. It has now been rechristened as Novo Nordisk India Private Limited.
In 1998, recognising the intense need to provide awareness and education in healthcare in India, the Novo Nordisk Education Foundation (NNEF) was founded. NNEF is a non-profit organisation, with a mission of ‘Enhancing healthcare through awareness and education’.
Novo Nordisk India’s portfolio of products and services deals with therapy areas in Diabetes, Human Growth Hormone and Haemostasis Management.
Novo Nordisk is synonymous with diabetes care inIndia . Novo Nordisk has introduced products and services hitherto not seen in the area of diabetes care in the country.
Over the last decade Novo Nordisk has been able to ensure that there is a marked improvement in the way people with diabetes live and work.
As part of our efforts to be at the forefront of bringing information to people with diabetes in India, we have attempted to highlight various aspects of diabetes which you would like to know about.
As part of our activities, we have always endeavoured to stay in touch with persons with diabetes as well as the medical fraternity.
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has…
Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal…
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
Terumo India’s Shishir Agarwal outlines the company’s strategic roadmap and growth trajectory in India, highlighting the organization’s focus on understanding the healthcare landscape, enhancing organizational capabilities, and diversifying the product…
The State of Gujarat is one of India’s most culturally diverse, the birthplace of ‘Father of the Nation’ Mahatma Gandhi, and the only place in the world where Asiatic lions…
Mohal Sarabhai, managing director of Ambalal Sarabhai Enterprises Limited (ASE) on transforming his family’s failing century-old business and creating new companies beneath the ASE Holdings umbrella, including a joint venture…
Dr Basant Garg explains the role and impact of the National Health Authority (NHA) in India, including its pivotal role in executing the Ayushman Bharat universal health coverage initiative. Dr…
Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting…
At a transformational moment for Indian pharma, OPPI’s Anil Matai outlines how the country’s government is more receptive to innovation and action-oriented than ever before, how the industry is increasingly…
Solid dosage forms like capsules and tablets make up over 70 percent of all medicines prescribed globally. In the view of Ajit Singh, chairman of Indian solid dosage form pioneer…
Pharmexcil’s Ravi Uday Bhaskar discusses how Indian pharma is rebuilding global confidence in its exports via a focus on quality, expanding into high-potential new markets like those in Latin America,…
See our Cookie Privacy Policy Here